The crowded drug pipeline for asthma treatments is an indication of the unmet needs of asthma patients in the United States. With the development of more efficient and sophisticated drug formulations, physicians, healthcare professionals, and patients have access to a wider variety of nebulizer solutions. Because of the highly competitive market, end users evaluate products largely by their cost, thus leading to a “commodity trend” where price is the only differentiating factor among products.
In order to change this ‘commodity trend’ where-in competition is primarily based on price, nebulizer manufacturers need to differentiate products based on quality and features by thoroughly educating patients, physicians and homecare providers.
New analysis from Frost & Sullivan (medicaldevices.frost.com), U.S. Nebulizers Markets, reveals that revenue in this market totaled $ 116.1 million in 2004 and is projected to grow to $147.6 million by 2011.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Nebulizers Markets, send an e-mail to Melina Gonzalez, Corporate Communications, at melina.gonzalez[.]frost.com with the following information: your full name, company name, title, telephone number, fax number, and e-mail address. Upon receipt of the above information, an overview will be sent to you by e-mail.
Increasing end-user education can also help simplify nebulizer technology and product usage. Due to multiple technologies and features, modern nebulizers are more complex. Patients usually do not know the importance of technical details such as droplets size and mechanical specificity that are required for precise drug delivery.
“The medications used with the nebulizers are under scrutiny and the joint commission on accreditation of healthcare organizations and the U.S. food and drug administration (FDA) have both issued recommendations to discontinue use of multi-dose bottled medications,” notes Frost & Sullivan Research Analyst Navendu Bhatt. “By using sterile, pre-measured, and pre-mixed unit-dose medications, it is possible to eliminate possible dosing errors and reduce nosocomial infections originating from hospital-like settings.”
Tubes form a standard part of nebulizer apparatus, and patients are thereby at an increased risk of being contaminated by air-born pathogens. Nebulizers depend on controlled breathing to deliver medication and the use of masks along with the nebulizers can help minimize such contamination risks.
Nebulizers have entered a market that has the presence of well-established competing technologies such as meter dose inhalers (MDIs) and dry powder inhalers (DPIs). While the late entry may slow penetration, this scenario could change once more products are introduced and physicians and patients gain confidence.
The number of patients with conditions treated by approved drug combinations delivered through nebulizers has continued to increase. While the increase in incidence and diagnosis of asthma and chronic obstructive pulmonary disease (COPD) is contributing to the rise in demand for nebulizers, they are also finding acceptance in new application for the treatment of conditions, such as diabetes, cancer, and migraine.
The U.S. nebulizers market is witnessing increased competition with the entry of overseas manufacturers. While this is leading to volatile prices, some manufacturers have established production facilities in Asia and South America to avail of lower labor and manufacturing costs.
“Competition is likely to even out and prices are expected to stabilize by 2006-2007,” says Bhatt. “While this may result in increased volumes and better revenues, future growth is likely to stem from the growing popularity of portable compressor nebulizers.”
U.S. Nebulizers Markets, part of the Medical Device subscription, analyses the U.S. market for nebulizer technologies such as conventional compressor, portable compressor, and ultrasonic. It provides manufacturers with key insights into drivers, restraints, and market opportunities. It further profiles emerging technologies and forecasts trends and growth across individual market segments, such as conventional compressor, portable compressor, and ultrasonic nebulizers. Analyst interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
U.S. Nebulizers Markets
Corporate Communications – Europe
P: +44 (0) 20 7915 7856
F: +44 (0) 20 7730 3343
Radhika Menon Theodore
Corporate Communications – Asia Pacific
P: +91 44 24314263 Ext: 312
Corporate Communications – India
P: +91 22 2832 4705 Ext: 131
Keywords in this release: nebulizers, U.S., compressor nebulizers, portable handheld compressor nebulizers, ultrasound nebulizers, asthma, chronic obstructive pulmonary disease, COPD, cancer, diabetes, migraine, meter dose inhaler, MDI, dry powder inhaler, DPI, research, information, market, trends, technology, service, forecast, market share